Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1624 1628 1629 1645
This examiner grants 43% of resolved cases
Liyuan Mou is an examiner in Tech Center 1600 and Art Unit 1624. He has 119 resolved cases, with an allowance rate of 42.9 percent. The median days to allowance is 1131. These figures suggest a difficult prosecution environment and a standard duration for this technology area.
The interview lift is 59.0 percent, which is a high value. This figure indicates that interviews are a powerful tool for obtaining an allowance with this examiner compared to the 42.9 percent baseline. A 59.0 percent lift suggests that the majority of successful cases may involve direct communication with the examiner.
With 119 resolved cases, the allowance rate and 1131 day median are established metrics for Art Unit 1624. The interview lift is the most important data point for practitioners to consider. Engaging in an interview appears to be an effective way to overcome the baseline allowance rate.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19219972 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | Non-Final OA | ANTECIP BIOVENTURES II LLC |
| 18005245 | LOW DOSE REGIMEN AND FORMULATION OF A 5-METHYL-1,2,4-OXADIAZOL-3-YL COMPOUND | Final Rejection | Eli Lilly and Company |
| 17595446 | DIETARY BUTYRATE AND ITS USES | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 18310238 | Niraparib Compositions | Non-Final OA | Merck Sharp & Dohme LLC |
| 18290772 | INHIBITING INTRACELLULAR PATHOGENS | Non-Final OA | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 18293144 | METHODS AND COMPOSITIONS FOR TREATMENT OF KRAS MUTANT CANCER | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18263341 | METHODS OF TREATING CANCER WITH KINASE INHIBITORS | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18699069 | COMPOSITION CONTAINING SESAMIN AND ERGOTHIONEINE OR SALT THEREOF | Non-Final OA | SUNTORY HOLDINGS LIMITED |
| 18546735 | PHENYLACETIC ACID DERIVATIVE, USE THEREFOR, AND PRODUCTION INTERMEDIATE THEREOF | Final Rejection | SUMITOMO CHEMICAL COMPANY, LIMITED |
| 18282099 | ALKENE QUINONE COMPOUNDS AND METHODS OF USE | Non-Final OA | University of Pittsburgh - Of the Commonwealth System of Higher Education |
| 19003405 | COMPOSITIONS FOR PREVENTING AND TREATING NEURODEGENERATIVE DISEASES | Non-Final OA | ARIBIO CO., LTD. |
| 18707971 | Compositions and Methods for Modulating the Effect of Beta-Blocker Activity in a Subject | Non-Final OA | Duke University |
| 18689852 | COMPOUNDS AND THEIR USES FOR TREATING NEURODEGENERATIVE DISEASE | Final Rejection | Academia Sinica |
| 18684205 | 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF | Non-Final OA | JACOBIO PHARMACEUTICALS CO., LTD |
| 17433440 | ONVANSERTIB FOR INHIBITING NON-ADRENERGIC CONTRACTION OF SMOOTH MUSCLE AND PROSTATE CELL PROLIFERATION | Final Rejection | Cardiff Oncology, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy